isradipine has been researched along with Arteriosclerosis in 38 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) is a randomized, double-blind, active-control trial to compare the effectiveness of two treatment regimens for the control of hypertension in reducing the rate of progression of early extracranial carotid artery atherosclerosis in hypertensive patients." | 5.07 | MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data. ( Applegate, WB; Byington, RP, 1991) |
| "Isradipine is a potent dihydropyridine calcium channel blocker." | 3.77 | Isradipine. ( Schachter, M, 1991) |
| " With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
| "The influence of hypertension and of treatment with the dihydropyridine calcium channel blocker isradipine on the morphology of the thoracic aorta and of the aortic tunica intima were studied." | 3.69 | Effect of long term isradipine treatment on the morphology of the endothelium in the aorta of spontaneously hypertensive rats. ( Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1994) |
| "108 male rabbits, aged 6 months, with experimental hypercholesterolemia and experimental abdominal aortic lesioning received different regimen of antiatherosclerotic treatment; 36 of them were treated with isradipine, a dihydropyridine calcium antagonist (0." | 3.68 | Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2. ( Angelberger, P; Gerakakis, A; Keiler, A; Lupattelli, G; Pirich, C; Sinzinger, H; Virgolini, I, 1992) |
| "Isradipine has a beneficial effect on in-vivo platelet function as evidenced by a decreased platelet deposition on vascular lesion sites and an associated prolonged platelet survival in patients with hypertension and active atherosclerotic lesions." | 2.68 | Effect of isradipine on in-vivo platelet function. ( Kritz, H; O'Grady, J; Pirich, C; Schmid, P; Sinzinger, H, 1997) |
| "Hypertension is a risk factor for the development of atherosclerosis and its complications, which are among the major causes of morbidity and mortality." | 2.67 | The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group. ( Bond, MG; Borhani, NO; Buckalew, V; Canossa-Terris, M; Gibbons, ME; Sowers, JR; Worthy, AJ, 1991) |
| "Isradipine is a new dihydropyridine calcium antagonist that is highly effective in lowering blood pressure." | 2.67 | A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). ( Bond, G; Brugger, S; Byington, R; Flack, JM; Grimm, RH, 1990) |
| " Nevertheless, experiments in atherosclerotic animals indicate that the dose has to be chosen more cautiously than for young animals, as the dose-response curve for several effects is bell-shaped." | 2.38 | Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity. ( Hof, RP; Rüegg, UT, 1991) |
| "In isradipine-treated groups I/M ratios were significantly decreased (0." | 1.30 | Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits. ( Donetti, E; Fumagalli, R; Paoletti, R; Soma, MR, 1997) |
| "Treatment with ramipril significantly improved maximum EDR to 53 +/- 3% (p < 0." | 1.29 | Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction. ( Beems, RB; de Wildt, DJ; Meijer, GW; Porsius, AJ; Riezebos, J; van Amsterdam, JG; Vleeming, W; Wemer, J, 1994) |
| "When isradipine was given either during cholesterol feeding and continued for four weeks following it (subgroup 5) or during the four weeks following cholesterol feeding (subgroup 6), loss of endothelium dependent relaxation and the accumulation of cholesterol in the aorta was prevented." | 1.29 | Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits. ( Kappagoda, CT; Kunjara-Na-Ayudhya, R; Thomson, AB, 1994) |
| "When isradipine was administered during the washout period, the volume of the intima per unit length of aorta fell to levels below those produced by cholesterol feeding for three weeks alone." | 1.29 | The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: a morphometric study. ( Kappagoda, CT; Skepper, JN, 1996) |
| " Dose-response curves to acetylcholine (ACh), noradrenaline (NA), phenylephrine (Phen) and angiotensin II (AII), were obtained in 6 cholesterol-fed and 6 control rabbits before and after isradipine (code name PN200-110) 100 micrograms kg-1." | 1.27 | Vasoconstrictor and vasodilator effects in normal and atherosclerotic conscious rabbits. ( Hof, A; Hof, RP, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (21.05) | 18.7374 |
| 1990's | 30 (78.95) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riezebos, J | 2 |
| Vleeming, W | 2 |
| Beems, RB | 2 |
| van Amsterdam, JG | 2 |
| Meijer, GW | 2 |
| de Wildt, DJ | 2 |
| Porsius, AJ | 2 |
| Wemer, J | 2 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Kobalava, ZhD | 1 |
| Hansson, L | 1 |
| Zanchetti, A | 1 |
| Ferrante, F | 1 |
| Ciriaco, E | 1 |
| Abbate, F | 1 |
| Laurà, R | 1 |
| Amenta, F | 1 |
| Bernini, F | 1 |
| Soma, MR | 2 |
| Corsini, A | 1 |
| Paoletti, R | 2 |
| Kunjara-Na-Ayudhya, R | 1 |
| Thomson, AB | 1 |
| Kappagoda, CT | 3 |
| Borhani, NO | 6 |
| Fet'kovská, N | 1 |
| Ulicná, L | 1 |
| Jakubovská, Z | 1 |
| Prisant, LM | 1 |
| Zemel, PC | 1 |
| Nichols, FT | 1 |
| Zemel, MB | 1 |
| Sowers, JR | 4 |
| Carr, AA | 2 |
| Thompson, WO | 1 |
| Bond, MG | 6 |
| Furberg, CD | 3 |
| Byington, RP | 5 |
| Gibbons, ME | 2 |
| Shi, H | 1 |
| Severs, NJ | 1 |
| Robenek, H | 1 |
| Mercuri, M | 1 |
| Borhani, PA | 1 |
| Buckalew, VM | 1 |
| Canossa-Terris, M | 2 |
| Kappagoda, T | 1 |
| Rocco, MV | 1 |
| Schnaper, HW | 2 |
| Skepper, JN | 2 |
| O'Grady, J | 2 |
| Kritz, H | 1 |
| Schmid, P | 1 |
| Pirich, C | 2 |
| Sinzinger, H | 5 |
| Donetti, E | 1 |
| Fumagalli, R | 1 |
| Craven, TE | 2 |
| Pahor, M | 1 |
| Miller, ST | 1 |
| Brugger, SB | 2 |
| Khoury, S | 1 |
| Flack, J | 1 |
| Fitscha, P | 3 |
| Lupattelli, G | 1 |
| Virgolini, I | 1 |
| Keiler, A | 2 |
| Gerakakis, A | 1 |
| Angelberger, P | 1 |
| Rauscha, F | 1 |
| Strickland, HL | 2 |
| Wilmoth, SK | 2 |
| Safrit, A | 1 |
| Phillips, R | 1 |
| Szostak, L | 1 |
| Hof, RP | 3 |
| Hof, A | 2 |
| Takiguchi, Y | 1 |
| Buckalew, V | 1 |
| Worthy, AJ | 1 |
| Rüegg, UT | 1 |
| Applegate, WB | 1 |
| Schachter, M | 1 |
| Grimm, RH | 1 |
| Flack, JM | 1 |
| Byington, R | 1 |
| Bond, G | 1 |
| Brugger, S | 1 |
| Weinstein, DB | 2 |
| Heider, JG | 2 |
| Enevold, GL | 1 |
| Borhani, NA | 1 |
| Weiss, K | 1 |
| Gazsó, A | 1 |
| Gludovacz, D | 1 |
| Habib, JB | 1 |
| Bossaller, C | 1 |
| Wells, S | 1 |
| Williams, C | 1 |
| Morrisett, JD | 1 |
| Henry, PD | 1 |
| Handley, DA | 1 |
| Van Valen, RG | 1 |
| Melden, MK | 1 |
| Saunders, RN | 1 |
| Pickens, CE | 1 |
| Lan, S | 1 |
| Su, CM | 1 |
6 reviews available for isradipine and Arteriosclerosis
| Article | Year |
|---|---|
Experimental and clinical effects of isradipine relevant to atherosclerosis.
Topics: Animals; Arteriosclerosis; Dose-Response Relationship, Drug; Humans; Isradipine | 1994 |
Antiatherosclerotic actions of isradipine.
Topics: Arteriosclerosis; Calcium Channel Blockers; Dihydropyridines; Humans; Isradipine; Lipid Metabolism | 1992 |
Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
Topics: Animals; Arteriosclerosis; Calcium Channel Blockers; Cardiovascular System; Disease Models, Animal; | 1991 |
Isradipine.
Topics: Angina Pectoris; Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Human | 1991 |
Antiatherogenic properties of calcium antagonists.
Topics: Animals; Arteriosclerosis; Calcinosis; Calcium; Calcium Channel Blockers; Humans; Ion Channels; Isra | 1987 |
Anti-atherogenic activity of the calcium channel blocker isradipine (PN-200-110): a novel effect on matrix synthesis independent of calcium channel blockade.
Topics: Animals; Arteries; Arteriosclerosis; Calcium Channel Blockers; Cells, Cultured; Cholesterol, Dietary | 1987 |
15 trials available for isradipine and Arteriosclerosis
| Article | Year |
|---|---|
The antiatherosclerotic effect of calcium antagonists in man--what did MIDAS actually show? Multicenter Isradipine Diuretic Atherosclerosis Study.
Topics: Arteriosclerosis; Carotid Arteries; Controlled Clinical Trials as Topic; Humans; Hydrochlorothiazide | 1995 |
MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group.
Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi | 1994 |
Carotid plaque associations among hypertensive patients.
Topics: Aged; Arteriosclerosis; Carotid Stenosis; Female; Georgia; Humans; Hydrochlorothiazide; Hypertension | 1993 |
Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study.
Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi | 1993 |
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Diastole; Disease Progression; Di | 1996 |
Effect of isradipine on in-vivo platelet function.
Topics: Adult; Aged; Arteriosclerosis; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Cell Survi | 1997 |
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
Topics: Arteriosclerosis; Blood Glucose; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Artery D | 1997 |
MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group.
Topics: Antihypertensive Agents; Arteriosclerosis; Dihydropyridines; Double-Blind Method; Female; Humans; Hy | 1992 |
Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group.
Topics: Arteriosclerosis; Calcium Channel Blockers; Carotid Artery Diseases; Coronary Artery Disease; Diuret | 1990 |
Interventional clinical trials using noninvasive ultrasound end points: the Multicenter Isradipine/Diuretic Atherosclerosis Study. The MIDAS Research Group.
Topics: Arteriosclerosis; Calcium Channel Blockers; Carotid Artery Diseases; Diuretics; Humans; Isradipine; | 1990 |
The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group.
Topics: Adult; Aged; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Dihydropyridines; Double- | 1991 |
MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data.
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Carotid Arteries; Diuretics; | 1991 |
Isradipine.
Topics: Angina Pectoris; Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Human | 1991 |
A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Carotid Artery Diseases; Double-Blind Method; Fema | 1990 |
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Clinical Trials as Topic | 1989 |
18 other studies available for isradipine and Arteriosclerosis
| Article | Year |
|---|---|
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Cyclic AMP; Diet, Ath | 1994 |
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Biomarkers; Cholesterol; Cholesterol, Die | 1994 |
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |
Effect of long term isradipine treatment on the morphology of the endothelium in the aorta of spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Endothelium, Vascular; Hypertension; Isradipine; Male; M | 1994 |
Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits.
Topics: Acetylcholine; Animals; Aorta; Arteriosclerosis; Cholesterol, Dietary; Disease Models, Animal; Dose- | 1994 |
[Inhibition of thrombocyte activity in atherogenesis and thrombogenesis using isradipine and other calcium antagonists].
Topics: Arteriosclerosis; Calcium Channel Blockers; Cholesterol, LDL; Humans; In Vitro Techniques; Isradipin | 1993 |
Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells.
Topics: Animals; Arteriosclerosis; Calcinosis; Calcium; Cell Movement; Chemotaxis; Foam Cells; Humans; Israd | 1996 |
The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: a morphometric study.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Calcium Channel Blockers; Cell Size; Ch | 1996 |
Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits.
Topics: Animals; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Dihydropyridines; Dose-Respon | 1997 |
Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cholesterol; Dihydro | 1992 |
The effect of concurrent administration of isradipine on the development of fatty streaks in the cholesterol-fed rabbit: a morphometric study.
Topics: Administration, Oral; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholesterol; Cholesterol, D | 1992 |
The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibition.
Topics: Animals; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Collagen; Cyclooxygenase Inhibitors; D | 1992 |
Comparative hemodynamic studies of isradipine and dihydralazine in atherosclerotic and normal rabbits.
Topics: Animals; Arteriosclerosis; Calcium Channel Blockers; Coronary Artery Disease; Dihydralazine; Electro | 1990 |
Detection and monitoring of asymptomatic atherosclerosis in clinical trials.
Topics: Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Humans; Hydro | 1989 |
Calcium blockers: antiatherogenic action by influencing the prostaglandin-system.
Topics: Adult; Animals; Arteriosclerosis; Calcium Channel Blockers; Diltiazem; Epoprostenol; Female; Humans; | 1989 |
Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110.
Topics: Animals; Aorta; Arteriosclerosis; Calcium Channel Blockers; Cholesterol, Dietary; Endothelium; Hemod | 1986 |
Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Blood Platelets; Blood Pressure; Carotid Arteries; | 1986 |
Vasoconstrictor and vasodilator effects in normal and atherosclerotic conscious rabbits.
Topics: Acetylcholine; Angiotensin II; Animals; Aorta, Thoracic; Arteriosclerosis; Blood Pressure; Calcium C | 1988 |